BlackRock’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,850,801
| Closed | -$927M | – | 5784 |
|
|
2025
Q4 | $927M | Buy |
12,850,801
+3,648,222
| +40% | +$236M | 0.02% | 723 |
|
|
2025
Q3 | $401M | Sell |
9,202,579
-134,255
| -1% | -$5.43M | 0.01% | 1236 |
|
|
2025
Q2 | $265M | Sell |
9,336,834
-580,637
| -6% | -$17.3M | 0.01% | 1443 |
|
|
2025
Q1 | $293M | Sell |
9,917,471
-14,895
| -0.1% | -$464K | 0.01% | 1363 |
|
|
2024
Q4 | $289M | Buy |
9,932,366
+205,447
| +2% | +$8.59M | 0.01% | 1438 |
|
|
2024
Q3 | $447M | Buy |
9,726,919
+1,104,406
| +13% | +$47.9M | 0.01% | 1158 |
|
|
2024
Q2 | $352M | Buy |
8,622,513
+2,456,522
| +40% | +$70.5M | 0.01% | 1236 |
|
|
2024
Q1 | $157M | Sell |
6,165,991
-330,602
| -5% | -$5.18M | ﹤0.01% | 1798 |
|
|
2023
Q4 | $58.8M | Buy |
6,496,593
+710,018
| +12% | +$4.75M | ﹤0.01% | 2379 |
|
|
2023
Q3 | $36.9M | Buy |
5,786,575
+27,829
| +0.5% | +$240K | ﹤0.01% | 2579 |
|
|
2023
Q2 | $63.9M | Buy |
5,758,746
+125,321
| +2% | +$1.57M | ﹤0.01% | 2335 |
|
|
2023
Q1 | $86.5M | Buy |
5,633,425
+347,251
| +7% | +$7.64M | ﹤0.01% | 2098 |
|
|
2022
Q4 | $117M | Buy |
5,286,174
+1,164,537
| +28% | +$17.4M | ﹤0.01% | 1892 |
|
|
2022
Q3 | $67.3M | Buy |
4,121,637
+189,975
| +5% | +$3.63M | ﹤0.01% | 2229 |
|
|
2022
Q2 | $57.1M | Buy |
3,931,662
+665,653
| +20% | +$9.9M | ﹤0.01% | 2394 |
|
|
2022
Q1 | $60.3M | Sell |
3,266,009
-31,471
| -1% | -$535K | ﹤0.01% | 2470 |
|
|
2021
Q4 | $78.4M | Buy |
3,297,480
+84,704
| +3% | +$2.02M | ﹤0.01% | 2369 |
|
|
2021
Q3 | $79.1M | Buy |
3,212,776
+512,411
| +19% | +$11.1M | ﹤0.01% | 2360 |
|
|
2021
Q2 | $66.7M | Buy |
2,700,365
+10,638
| +0.4% | +$247K | ﹤0.01% | 2505 |
|
|
2021
Q1 | $58.7M | Buy |
2,689,727
+660,470
| +33% | +$16.2M | ﹤0.01% | 2521 |
|
|
2020
Q4 | $51.8M | Buy |
2,029,257
+734,652
| +57% | +$21.4M | ﹤0.01% | 2449 |
|
|
2020
Q3 | $36.4M | Buy |
1,294,605
+694,605
| +116% | +$20.1M | ﹤0.01% | 2480 |
|
|
2020
Q2 | $17M | Buy |
+600,000
| New | +$17.3M | ﹤0.01% | 2885 |
|
Other funds holding RNAM
BlackRock's RNAM Position: Q1 2026 in Review
BlackRock sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 12,850,801 shares — an estimated $927M sold.
BlackRock first reported a position in RNAM in Q2 2020 and held it in 23 quarters. The position peaked at $927M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- BlackRock reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 12,850,801 Avidity Biosciences shares in Q1 2026, an estimated $927M.
- BlackRock first reported a position in Avidity Biosciences in Q2 2020 and held it in 23 quarters.
- BlackRock's Avidity Biosciences position peaked at $927M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.